Objective To assess the effect of admission cardiotocography (ACTG) versus intermittent auscultation (IA) of the fetal heart (FH) in low-risk pregnancy during assessment for possible labour on caesarean section rates.
Introduction
Monitoring of the fetal heart rate (FHR) throughout pregnancy, labour and birth is central to the assessment of fetal wellbeing to optimise fetal and neonatal outcomes. A precursor to FHR monitoring during labour is an assessment of the FHR on admission to the labour ward or labour assessment room in women with signs and symptoms of possible labour onset. This is usually performed by either intermittent auscultation (IA), which involves listening to and counting the fetal heart (FH) for one or more minutes, or admission cardiotocography (ACTG), a screening test consisting of an approximately 20-minute electronic recording of the FHR and uterine activity. The rationale for labour admission assessment of the FHR is to try to identify those babies at greater risk of intrapartum fetal compromise, and hence, who might benefit from continuous cardiotocography (cCTG) during labour. 1 However, there is evidence of a lack of benefit supporting the use of ACTG in low-risk pregnancy with many guidelines recommending the use of IA in the absence of risk factors for continuous monitoring of fetal wellbeing.
2, 3 However, previous trials informing these guidelines have evaluated the effects of ACTG on women in the context of diagnosed labour, either spontaneous onset or induced labour. [4] [5] [6] [7] Recommendations have called for studies to evaluate the effects of ACTG on women admitted with signs and symptoms of possible labour onset, when ACTG is applied, generally, and before a formal diagnosis (e.g. following an assessment of cervical dilatation and effacement on vaginal examination) of spontaneous or induced labour. 8, 9 The objective of this paper is to report the findings of a multicentre randomised trial that compared ACTG with IA of the FHR in low-risk healthy pregnant women presenting with signs and symptoms of possible labour onset, and before confirmation of established labour, on rates of caesarean section, obstetric intervention and neonatal morbidity. The trial is registered with http://www.isrctn.com/ ISRCTN96340041.
Methods

Design and participants
A two-group, parallel, randomised trial was undertaken in three maternity units in the Republic of Ireland between May 2008 and June 2012. Two units were tertiary centres with approximately 8000 and 3000 births per annum, and the other unit was a regional centre with an annual birth rate of approximately 4000. Participants were healthy lowrisk pregnant women attending any of the three study sites with signs and symptoms of possible labour onset. Eligibility criteria included gestation between 37 +0 and 40 +6 completed weeks of pregnancy, age ≥ 18 years, and an ability to understand study information and give written informed consent. Women were excluded if any of the following conditions applied to them: previous caesarean section, preeclampsia, diabetes, gestational age greater than 40 +6 or less than 37 +0 weeks, undergoing induction of labour, rupture of membranes for longer than 24 hours, temperature > 37.5°C on admission, body mass index > 35 kg/m 2 at antenatal booking, maternal age > 40 or < 18 years, assisted conception in this pregnancy, previous stillbirth or neonatal death, small-for-gestational-age (< 10th centile), oligiohydramnios, polyhydramnios, abnormal Doppler artery velocimetry, multiple pregnancy, breech presentation, reduced fetal movements on two or more occasions, meconium stained liquor, fetal congenital abnormality, or serious maternal medical disease (cardiac or vascular disease, epilepsy, liver disease, hyperthyroidism, or abnormal renal function).
Enrolment procedures
A two-stage process of consent was used. Women attending the antenatal clinic between 32 and 40 weeks of gestation were given written information about the study and asked to consider participation before their admission to the hospital with signs and symptoms of possible labour onset. A sticker showing 'ADCAR study information given' was placed on the front cover of their maternity notes highlighting that they had received the study information. Women attending the labour ward/labour assessment unit between 37 +0 and 40 +6 weeks of gestation with signs and symptoms of possible labour onset (e.g. regular uterine contractions, rupture of membranes, maternal report of suspected labour), and who had received the study information, were screened for eligibility to participate in the trial using a trial screening and register form. Screening was conducted by the admitting midwives, on a 24-hour basis, as women presented. Women who were screened eligible were invited to participate in the trial and sign the study consent form. Following consent, participating women were randomised to receive ACTG or IA (allocation ratio of 1:1) by the admitting midwife using a remote central telephone randomisation service (ALEA, a software package developed to support randomisation in healthcare research in Europe). Randomisation occurred before a formal diagnosis of labour; eligible women with signs and symptoms of possible labour onset were entered into the trial irrespective of whether they were subsequently found to be in established labour or not, or whether their admission was for nonreassuring FHR following assessment. The randomisation sequence was computer generated, using block randomisation, with random block sizes of two or four, and stratification by study site. Due to the nature of the intervention, blinding was not possible at participant and clinician level; however, the biostatistician performing the analysis was blinded to group allocation during the analysis process.
Intervention group
Women randomised to the intervention received IA of the FH, performed by the admitting midwife, on admission for possible labour onset, using either a Pinard stethoscope or a hand-held Doppler ultrasound device. Although the chosen method of IA was not recorded routinely, the likelihood was that a Doppler device was used in the majority of cases as this is the more commonly adopted method for IA in the trial settings. IA included abdominal palpation of uterine contractions and assessment of the FHR for at least 60 seconds after a uterine contraction. Conversion to CTG occurred where IA revealed a baseline FHR of < 110 beats/ minute or > 160 beats/minute or any decelerations in the FH; or if any other risk factors developed during admission, which warranted cCTG, or the clinician caring for the woman had any other cause for concern. Following IA, where the above interpretation criteria were met, subsequent care during labour was in accordance with standard care; that is, monitoring of the FHR by IA for 1 minute at least every 15 minutes in the first stage and at least every 5 minutes in the second stage of labour or conversion to cCTG if clinically indicated. Women assessed as not being in established labour following randomisation were either discharged home or admitted to the antenatal ward to await further signs and symptoms of labour. On readmission to the labour ward or labour assessment room, with further signs and symptoms of labour, and where the trial screening and register form criteria for low-risk continued to be met, women received IA of the FHR, with subsequent care in accordance with the care as described above.
Control group
Women randomised to the control group received 20-minutes of ACTG on admission to the labour ward or labour assessment room, as was standard care in the three participating hospitals. If the baseline FHR was between 110 and 160 beats/minute, baseline variability was >10 beats/minute, there were more than two accelerations present, and decelerations were absent then the tracing was classified as normal and discontinued, and the findings were documented. The uterine contraction pattern was also assessed. If, following the ACTG, the above interpretation criteria were met, the woman's care was in accordance with standard care; i.e. IA for monitoring of the FH during labour or conversion to cCTG as warranted. If the interpretation criteria were not met on ACTG, CTG was continued and interpretation of the tracing was used to inform the subsequent care of the woman, as was current practice. Women assessed as not being in established labour following randomisation were either discharged home or admitted to the antenatal ward to await further signs of possible labour onset. On readmission to the labour ward or labour assessment room with further signs and symptoms of labour, women received ACTG with subsequent care in accordance with care as described above.
Outcome measures
Although a core outcome set for intrapartum fetal assessment is registered with the Core Outcome Measures in Effectiveness Trials (COMET) database (http://www.cometinitiative.org/studies/details/741?result=true), this core outcome set is not yet developed. In the absence of a core outcome set, our outcome measures were as follows. The primary outcome measure was overall incidence of caesarean section. Maternal secondary outcome measures were cCTG during labour (defined as cCTG for > 75% of labour duration), fetal blood sampling, augmentation of labour with oxytocin, augmentation of labour with artificial rupture of membranes, duration of labour, epidural analgesia, pethidine analgesia and mode of birth. Neonatal outcome measures were metabolic acidosis (defined as an umbilical artery blood pH < 7.0, and a base deficit of > 12.0 mmol/ l), 1 hypoxic ischaemic encephalopathy, seizures (either apparent clinically or detected by electroencephalographic recordings), neonatal Apgar scores at 1 and 5 minutes, admission to the neonatal intensive care unit (NICU), length of stay in NICU (in days), neonatal death, stillbirth, intracranial haemorrhage (as determined by cranial ultrasound/magnetic resonance imaging report), meconium aspiration (as determined on X-ray) and any neonatal resuscitation. The following baseline characteristics were also measured: maternal age, gestation at birth, parity, neonatal birthweight and neonatal congenital abnormality (undetected before birth).
Public and patient involvement
A maternity service user was a member of the Trial Steering Committee. Pregnant women were involved as participants in the trial.
Sample size assumptions and estimates
A retrospective clinical audit of 600 women was conducted in two hospitals in 2007 to determine the number of women who would potentially be eligible to take part in the study and to determine the incidence of caesarean section in this low-risk maternity sample. The audit found that 55% of women, across the two hospitals, met the eligibility criteria, and the caesarean section rate was 5.2%. With 80% power and a set at < 0.05, a sample size of 5776 women (2888 per group), allowing for a 10% attrition rate, was required to detect a 30% reduction in the incidence of caesarean section (i.e. from 5.2% with ACTG to 3.6% with IA) allowing for a 10% attrition rate. Calculations were performed using SAMPLE POWER.
Data collection and statistical analysis
Data were extracted from the Maternity Information Systems in each hospital and from hard copy clinical notes as required. Predesigned data extraction forms were developed, piloted and refined for collecting the relevant data. All data were entered into SPSS (Version 16) in preparation for analysis. For dichotomous data, relative risks (RR) with 95% CI were calculated. For continuous data, mean differences (MD) with 95% CI were calculated. For the primary outcome, incidence of caesarean section, an unadjusted analysis, followed by a secondary exploratory analysis adjusting for a mother's age, parity and site (and possible interactions), was performed. All comparisons for secondary outcomes were unadjusted. All analyses adhered to 'intention-to-treat'; however, as a number of women were discharged home 'not in labour' following randomisation (see Table 1 ), and became ineligible subsequently, we performed a sensitivity analysis for the primary outcome excluding these women.
Ethical considerations
Ethical approval to conduct the study was granted by the 
Results
During the study period, 14 928 women who had received the study information were assessed for eligibility to participate in the study. Of these, 6771 (45%) were screened eligible, of whom 3045 (45%) consented and participated. Eleven (0.4%; six ACTG, five IA) women were lost to follow up, resulting in data from 3034 women available for analysis. Table 1 presents participant characteristics by group; no differences in baseline characteristics were found. Figure 1 illustrates the recruitment and randomisation process.
Primary outcomes
A total of 235 women had a caesarean section; 130 (8.6%) in the IA group and 105 (6.9%) in the ACTG group. The results demonstrate no significant difference between the groups in relation to caesarean section rates observed (unadjusted RR 1.24, 95% CI 0.97-1.59, P = 0.08). The primary reasons for caesarean section in the IA and ACTG groups, respectively, were caesarean section for abnormal FHR pattern (n = 84 and n = 71), emergency caesarean section for reasons other than abnormal FHR pattern (n = 42 and n = 34), and elective caesarean section (n = 4, IA group only).
Secondary outcomes
There were no statistical differences in any of the secondary outcomes, other than the use of cCTG during labour, which was significantly less in the IA group (RR 0.90, 95% CI 0.86-0.93), P < 0.00001). Table 2 presents the results for the secondary outcomes.
No fetal or neonatal deaths (up to discharge home) were observed in the study. Ninety-six babies in total were admitted to the NICU/special-care baby unit. Table 3 summarises reasons for admission and outcome details.
Secondary exploratory analyses
A sensitivity analysis, excluding women who became ineligible post-randomisation, found no difference in caesarean section between the groups (IA, n = 227, 15% and ACTG, n = 249, 16%; RR 1.19, 95% CI 0.86-1.65). To further explore the difference between the groups in the primary outcome, adjusting for mother's age, parity and site, no significant difference between the groups in caesarean section was found (adjusted RR 1.22; 95% CI 0.93-1.60, P = 0.16). There was no evidence of a significant site by allocation interaction in the adjusted models. The proportions of caesarean sections by allocation (IA versus ACTG, respectively) and by study site were 9% versus 5.9% (site A), 10.8% versus 8.7% (site B) and 5.4% versus 6.0% (site C); significantly fewer caesarean sections occurred in the ACTG group in site A (P = 0.046), but no differences were observed between the groups in site B (P = 0.27) or in site C (P = 0.69).
Discussion
Main findings
The findings of our comparison of IA versus ACTG, in over 3000 low-risk women presenting with possible labour onset, provide no evidence of a significant difference in any of our measured primary and secondary outcomes other than a decrease in use of cCTG associated with being randomised to IA. These findings, while offering, in the main, equivalence for choice of method, reflect current clinical guideline recommendations for IA use during labour admission in low-risk, healthy pregnant women 2,3 and concur with previous studies where significantly lower rates of cCTG use during labour were experienced by women receiving IA. 4, 5 Although our finding of no significant difference in caesarean birth between IA and ACTG is similar to findings in other studies, [4] [5] [6] [7] our study differs whereby a higher incidence of caesarean birth, albeit statistically nonsignificant, was observed in the IA group compared with the ACTG (8.6% and 6.9%, respectively). Previous trials report higher rates of caesarean sections in ACTG groups; for example, for IA versus ACTG, Mires et al. 4 report caesarean rates of 3.6% and 5.1%, 4 Mitchell 7 reports rates of 7.7% and 8.7%, and Cheyne et al. 6 report rates of 6.2% and 8.9%. This finding in our study is surprising given the significantly increased use of cCTG with ACTG and the known association between cCTG during labour and higher caesarean rates in low-risk women when compared with IA of the FHR. 1 Although we performed secondary exploratory analyses on the outcome of caesarean section, we remain uncertain as to why there was a nonsignificant trend towards higher rates of caesarean birth in the IA group. However, an important difference in our study is that women were randomised before a formal diagnosis of labour. One hypothesis is that ACTG has a different effect on mode of birth for women with and without a diagnosis of labour. Another possible explanation might simply be a 'chance' finding. Given that our study failed to achieve target recruitment, it is reasonable to suppose that had we succeeded in achieving our sample size estimate, the trend towards caesarean birth with IA may have become more balanced between groups, or even reversed. A further intriguing finding in our study was the high rate of acceleration of labour in both the IA (55%) and ACTG (57%) groups, the majority of which was by artificial rupture of membranes. This finding, rather than reflecting abnormally slow labours, per se, or study sample bias, is most likely because of active management of labour practices, 11 which are common in many maternity units in Ireland.
Strengths and limitations
Over half of women eligible to participate in the ADCAR trial declined to do so. Although similar rates of eligible consenting women have been found in another large maternity care trial in Ireland, 12 timing of consent (i.e. women presenting with signs of possible labour) and approaches to taking consent (e.g. staff preferences for CTG use 13 ) may have impacted on consent rates. Failing to recruit a significant portion of eligible women has the potential to introduce selection bias, and this needs to be considered when interpreting the results of the study.
Failing to recruit our sample size estimate is a further study limitation. Our sample size of 1521 and 1513 for the two groups achieves a power of 69.3% (based on the same a priori sample size assumptions of a 0.05 to detect a 30% reduction in the incidence of caesarean section from 6.9% with ACTG identified in this study). Despite responsive efforts to increase recruitment, including embedding a Study Within A Trial (SWAT) (https://www.qub.ac.uk/site s/TheNorthernIrelandNetworkforTrialsMethodologyResearc h/SWATSWARInformation/) to assess the effectiveness of a site visit on recruitment, 14 extending the trial to a third site (site C) and extending the time frame to conduct the trial, achieving monthly recruitment targets was challenging, with monthly rates rarely exceeding 50% of expected targets. Achieving target recruitment is known to challenge almost all triallists, with evidence to suggest that < 50% of trials will achieve their target rates within the planned time frames. 15, 16 Nevertheless, recruiting less than the number of expected participants to our study does limit the interpretation of the results. Reasons for low recruitment to this study were multi-fold, and reflect evidence that highlights clinician preference for CTG use due to fear of litigation and a perceived view of CTG technology assisting staff with workload burden and staff shortages. 13 Furthermore, given that the rationale for either IA or ACTG use on labour admission is to assess fetal wellbeing, ideally a trial of this type would be powered to detect a difference between the groups in a serious adverse neonatal outcome, such as neonatal mortality. However, to do so would require the recruitment of many thousands of women (> 50 000) to the trial, and considerable resources. In the absence of a core set of outcome measures evaluating the effects of ACTG, we measured and reported a relatively large number of prespecified outcomes. We acknowledge that this increased multiple testing and therefore the risk of a higher false-positive error rate.
Acknowledging these limitations, our study provides evidence for FHR assessment based on a considerably large sample of women and presents the third largest of five trials examining IA and ACTG during labour admission. [4] [5] [6] [7] Furthermore, it is the first trial, that we are aware of, which evaluates IA and ACTG use in women presenting with signs and symptoms of possible labour onset, and before confirmation of established labour, which is more likely to accurately reflect how ACTG is applied in practice in many settings.
Interpretation
Although the evidence from previous randomised trials, and a systematic review, for IA use on labour admission, is compelling, 9 conflicting findings from recent non-randomised studies continue to provide some clinicians with a rationale for ACTG use. Rahman et al. for example, in a study evaluating the role of ACTG, reported a low risk of fetal compromise during labour for women with a reactive ACTG compared with women with equivocal and ominous ACTGs; 6.9%, 39.9% and 84.6%, respectively (P < 0.001). 17 The incidence of thick meconium-stained liquor, admission to NICU and neonatal mortality were also significantly higher in the ominous and equivocal groups compared with the reactive ACTG group and operative birth for suspected fetal compromise was required in 5.5% (n = 8/145) of women in the reactive group compared with 27.8% (n = 5/18) in the equivocal group and 84.6% (n = 11/13) of women in the ominous group. Bhartiva et al. also report a significant correlation (P = 0.001) between nonreassuring ACTG and meconium-stained liquor in low-risk women, although statistically insignificant correlations were found for low Apgar scores, NICU admission and mortality. 18 Contrastingly, Akhavan et al., in their recent study of 425 pregnant women of whom 142 (33.4%) had abnormal ACTGs, assert that an abnormal ACTG was predictive of caesarean section, intrauterine growth restriction and low Apgar scores (< 7) at birth. 19 
Conclusion
This trial demonstrates that outcomes were not different between IA and ACTG for women with signs of labour with the exception of increased cCTG use associated with ACTG. In particular, our study presents evidence for IA compared with ACTG in healthy pregnant women with signs and symptoms of possible labour onset, before a formal diagnosis of established labour. Further research comparing IA and ACTG use before the diagnosis of spontaneous labour in selected samples of women presenting with signs and symptoms of possible labour is required. Further research is also required comparing the use of IA or the use of ACTG in women with confirmed compared with unconfirmed labour during labour ward admission.
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